Project Grant R01HL170012
Award Date
4/17/24
Completion Date
3/31/28
Dollars Obligated
$624K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute of MIT and Harvard to investigate the genetic basis and underlying mechanisms of heart failure (HF). The project aims to leverage high-throughput functional genomic approaches, including cell painting and Perturb-seq, to systematically assess the impact of HF-associated genetic risk loci on...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $782,672 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Brigham & Women's Hospital. The grant funding will support research to identify previously unrecognized genetic causes of congenital heart disease (CHD). The project aims to assess the contributions of non-coding and rare coding variants to unexplained CHD cases, using a combination of cell-based functional assays, single-nucleus RNA...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $599,342 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the University of California, Davis to identify key molecular and cellular changes in heart failure with preserved ejection fraction (HFpEF), and investigate the impact of HFpEF phenotypic heterogeneity on disease mechanisms and potential therapies. The project aims to develop refined computational models informed by novel functional and transcriptomic data,...
This $558,291 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of Colorado-Denver to investigate the role of the enzyme 15-PGDH in cardiac fibrosis and heart failure. The research aims to test the hypothesis that inhibiting 15-PGDH can prevent and reverse the activation of cardiac fibroblasts, which leads to pathological cardiac fibrosis. This 4-year project, running from Jul 10, 2024 to...
This Project Grant award R01HL168247 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $827,665 to the New York Genome Center, Inc. (NYGC) to develop scalable methods to identify causal genetic variants, relevant cell types, and target genes associated with cardiovascular disease (CVD) risk.
The key products and services to be delivered include: 1) creating a reference atlas of 3D enhancer maps for 13 blood...
The University of Colorado-Denver received a $126,059 Project Grant from the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports a 5-year research project to investigate the systems biology of acute and chronic multi-organ failure in children with congenital heart disease (CHD).
Specifically, the research will utilize proximity extension assay technology to perform longitudinal measurement of the circulating proteome...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will develop, validate, and determine the clinical utility of a precision genetic testing approach guided by machine learning algorithms. The $756,895 award to Duke University, with sub-awards to Mayo Clinic and the Medical University of South Carolina, aims to enhance the diagnosis of two monogenic cardiovascular disorders: hypertrophic...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the pathogenic roles and molecular mechanisms of histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure.
The $601,563 award, with a performance period from September 1, 2024 to August 31, 2027, will fund research conducted by the University of Texas Health Science...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $487,567 to Indiana University to conduct integrative genomic analysis and develop high-dimensional risk prediction models for congenital heart defects (CHDs). The research aims to identify genetic variants and biological pathways associated with CHDs, as well as build predictive models leveraging genetic, epigenetic,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,658,837.00 to the University of Colorado-Denver to investigate the role of glycosphingolipids in driving cardiac and immune cell dysfunction in patients with hypoplastic left heart syndrome (HLHS).
The research aims to 1) determine whether accumulation of the glycosphingolipid laccer elicits a pro-inflammatory and...